Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Cellular Immunotherapy for SSc

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    Project Summary Systemic sclerosis SSc is a systemic autoimmune disease that results in widespread fibrosis of the skin and internal organs vascular dropout and autoantibody formation SSc has the highest case fatality rate of any systemic autoimmune disease and there remain for FDA approved therapies Analysis of gene expression data on samples collected from SSc patients strongly indicates th ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows

    SBC: 490 BIOTECH INC            Topic: 300

    Development of a high throughput screen to detect the effects of both preand postbiotransformed compounds for enhanced content drug discovery workflows Project Summary This Small Business Innovation Research Phase II project will build upon our successful Phase I demonstration that substrate free autobioluminescent signal generation can detect both the preand post biotransformed metabolic impacts ...

    SBIR Phase II 2017 Department of Health and Human Services
  3. Novel Inhibitors of PSMB and PSMB for the Treatment of Multiple Myeloma

    SBC: InhiProt            Topic: 103

    Multiple myeloma is incurable hematologic malignancy with an expected median survival of years The proteasome inhibitors bortezomib carfilzomib and the recently approved ixazomib are a mainstay of current myeloma treatment Despite an initial response rate approaching to proteasome inhibitor containing combinations all patients relapse and eventually become resistant to any treatments ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Development of PEGylated MTI for the treatment of relapsed Myeloma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Modulation Therapeutics is developing a first in class cyclic peptide coined MTI for the treatment of multiple myeloma The company currently has a license for the parent molecule which has been awarded a patent covering the intellectual property for both composition of matter and use in cancer in the US and Europe Modulation Therapeutics is now poised to further advance this class ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. A single-cell device to capture and analyze rare T-cells from solid tumors.

    SBC: IsoPlexis            Topic: 102

    Checkpoint inhibitors towards targets such as PDand PD Lare being developed to activate quiescent T cells embedded in tumors and enable them to recruit the rest of the immune system to fight a cancer massHow these new cures reactivate the relatively few Tumor Infiltrating LymphocytesTILsenabling the release of a complex message of cytokines to recruit the immune systemthus impacting treatment effi ...

    SBIR Phase II 2017 Department of Health and Human Services
  7. Robust Predictor of Breast Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: 103

    Summary Approximatelymillion women in the United States are at high risk for developing breast cancerbased on inheritance of a germline mutation in a gene in the double strand breakDSBrepair and cyclin checkpoint pathwaysMany are unaware of their genetic predispositionsbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in these genesbut i ...

    STTR Phase I 2017 Department of Health and Human Services
  8. Osteopontin targeted therapy for primary CNS lymphoma

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Abstract Primary central nervous system lymphoma PCNSL is an aggressive brain tumor with a dire unmet therapeutic need It has an overall incidence of per person years and is regarded as an orphan disease with potential for fast track approval Our group made a discovery via gene expression analysis that osteopontin OPN is the most upregulated gene in PCNSL compared to its non CNS ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting the checkpoint regulator VISTA for treatment of inflammatory disease

    SBC: Immunext, Inc.            Topic: R

    ImmuNext has identified and developed a putative lead anti VISTA monoclonal antibodymAbthat we aim to bring to the clinic for the treatment of human autoimmune diseaseVISTA is a member of the highly successful negative checkpoint regulatorNCRfamily of drug targetswhose members have demonstrated proven efficacy in inducing long term remissions in human cancersWe contend that antibodies that suppres ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Complex Dimensional in Vitro Human Skin Tissue Models for Scleroderma

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    Abstract Project Summary Scleroderma Systemic Sclerosis SSc is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction fibrosis and inflammation One in three patients dies within years of diagnosis giving SSc the highest case fatality rate of any systemic autoimmune disease A lack of biologically relevant human SSc disease models has created a critical ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government